Anti-contractile and anti-proliferative responses in human pulmonary arterial smooth muscle cells induced by ACT-333679, the active metabolite of selexipag, a non-prostanoid selective prostacyclin receptor agonist

J. Gatfield, K. Menyhart, O. Nayler (Allschwil, Switzerland)

Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs

Session: Pulmonary hypertension: novel targets and drugs
Session type: Thematic Poster Session
Number: 2353

Disease area: Pulmonary vascular diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Gatfield, K. Menyhart, O. Nayler (Allschwil, Switzerland). Anti-contractile and anti-proliferative responses in human pulmonary arterial smooth muscle cells induced by ACT-333679, the active metabolite of selexipag, a non-prostanoid selective prostacyclin receptor agonist. Eur Respir J 2014; 44: Suppl. 58, 2353

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

Michael Klein (München, Germany) - 07.09.2014 23:57
hello, excellent poster! is it possible to receive the poster?thank you, best wishes,michael klein

You must Login to comment this presentation.

Related content which might interest you:

Neuron-derived orphan receptor 1 mediated human pulmonary arterial smooth muscle cells proliferation via cyclin D1 Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014
PKCalpha deficiency in mice is associated with pulmonary vascular hyperresponsiveness to thromboxane A₂ via increased TXA₂ receptor expression Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014
Nuclear factor-kappa B inhibition exerts anti-remodelling effects in pulmonary arterial smooth muscle cells Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014
Obligatory role of MEK/ERK/RSK90 in the mitogenic responses of human pulmonary artery smooth muscle cells Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014
Comparison of current therapies against endothelin-induced growth in pulmonary smooth arterial muscle cells (PASMCs) derived from patients with pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014
Anti-fibrotic effects of pirfenidone on pulmonary arterial vascular smooth muscle cells Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016
Treprostinil prodrugs for pulmonary arterial hypertension evaluated in cAMP profiling studies in live CHO-K1 cells Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014
NMDA receptor crosstalk with PDGFR-β and BMPR2 is involved in smooth muscle cell proliferation in pulmonary arterial hypertension Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016
Acid sphingomyelinase, a novel pathway for pulmonary vasoconstriction. Activation by apoptotic T cell microparticles and Fas ligand Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014
Role of endothelin B receptor in Th2-induced pulmonary vascular hyperresponsiveness Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013
Nuclear IL-33 arguments ST2 receptor expression in pulmonary arterial endothelial cells: Implication in the pathogenesis and progression of pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014
Antiproliferative effects of drugs affecting different signalling pathways on rat and human pulmonary artery smooth muscle cells Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015
MicroRNA-155 controls pulmonary artery fibroblast cell signalling and proliferation in a knockout mouse model: A role in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014
Activation of AMPK inhibits pulmonary arterial remodeling Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015
Prevention of monocrotaline-induced pulmonary vascular and myocardial remodeling by the selective neutrophil elastase inhibitor BAY 85-8501 Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014
Anti-remodeling potencies of the soluble guanylate cyclase activator BAY 41-2272 in human lung fibroblasts Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014
Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011
Insulin-like growth factor-1 contributes to the pulmonary artery smooth muscle cell proliferation in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014
M2 macrophages derived from patients with idiopathic pulmonary arterial hypertension are susceptible for apelin-mediated suppression of pro-inflammatory cytokines Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014
Endothelial-derived MIF contributes to pulmonary endothelial cell proliferation in human pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015